A Randomized, Double-blind, Double-dummy, Two Period, Two Treatment Cross-over Pharmacodynamic and Pharmacokinetic Study of Clopidogrel Given as 5-day Repeated Oral Doses (300 mg Loading Dose Followed by 75 mg/Day and 600 mg Loading Dose Followed by 150 mg/Day) in 4 Different Groups of CYP2C19 Genotyped Healthy Male and Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2011
At a glance
- Drugs Clopidogrel (Primary)
- Indications Acute coronary syndromes; Angina pectoris; Atherosclerosis; Cardiovascular disorders; Congenital heart defects; Embolism and thrombosis; Heart failure; Ischaemic heart disorders; Myocardial infarction; Peripheral arterial occlusive disorders; Stroke; Unstable angina pectoris
- Focus Pharmacodynamics
- Sponsors Sanofi
- 27 Aug 2010 Trial phase changed from IV to I as reported by ClinicalTrials.gov.
- 18 May 2010 New trial record